BXRX Baudax Bio

Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held virtually December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020; meetings may be requested through Piper Sandler.

A pre-recorded fireside chat with Ms. Henwood is now available on the Piper Sandler conference site and on the “Events” page within the Investors section of the Baudax Bio website at . The recording will be available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential COX-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit .

CONTACT:

Investor Relations Contact:

Argot Partners

Sam Martin / Claudia Styslinger

(212) 600-1902



Baudax Bio, Inc.

Ryan D. Lake

(484) 395-2436

Media Contact:

Argot Partners

David Rosen

(212) 600-1902



EN
30/11/2020

Underlying

BXRXBaudax Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Baudax Bio

 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces Corporate Update

Baudax Bio Announces Corporate Update Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking...

October 18, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for T...

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinic...

September 28, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio to Participate in the H.C. Wainwright Global Investment Con...

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-1...

September 7, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces Distribution of Series C Preferred Stock to Holde...

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par va...

August 23, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At...

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warra...

August 17, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch